International Seaways' H1 FY2026 TCE revenue and net income surged 104.7% and 422.5% YoY, driven by elevated spot charter rates. Read why INSW stock is a buy.
Marcus' theatres outperformed the domestic box office, with revenue up 14.4% and adjusted EBITDA margin reaching 18.7% LTM. Read why MCS stock is a Buy.
Verastem is performing commercially with Avmapki Fakzynja Co-pack and advancing in the clinic with its KRAS G12D inhibitor. Learn why VSTM stock is a buy.
Between 1 October 2025 and 1 October 2026, Nike's percentage of market capitalization on loan climbed from 0.97% to 6.97%, an increase of 6.00 percentage points. Read more here.
Arcutis Biotherapeutics' fair value is estimated at $24.41 per share, with upside contingent on clinical wins. Read why ARQT stock is downgraded to a hold.